SANTA CLARA, CA / ACCESS Newswire / February 4, 2026 / Expert Intelligence™, a startup building AI systems that automate expert decision-making in regulated laboratory environments, today announced it has raised a $4.7M seed round led by Sierra Ventures with participation from TSVC and Acorn Pacific Ventures.
Founded by Lalin Theverapperuma, Ph.D., a veteran AI and machine learning engineer with more than 20 years of experience at Apple, Meta, Intel, and Bosch, Expert Intelligence’s platform operates directly on raw instrument data, rather than relying on downstream reports or large labeled datasets.
At the core of the platform is the Limited Sample Model (LSM), a new approach designed to learn how expert analysts make decisions using a small number of samples. Unlike large language models or traditional ML systems that require massive datasets, LSM is built for regulated environments where data is scarce, highly contextual, and tightly controlled.
“Expert Intelligence is building foundational infrastructure for autonomous decision-making in some of the most demanding environments in the world,” said Ben Yu, Managing Partner at Sierra Ventures. “Their ability to learn from limited data and operate at the instrument level unlocks a category of automation that simply wasn’t possible before in regulated labs.”
Since commercial deployments in early 2025, Expert Intelligence has secured customers across analytical testing workflows in pharmaceuticals, drug manufacturing, and food and beverage safety, supporting use cases such as automated result review, anomaly detection, and expert-level decision consistency. The company plans to expand into additional lab-driven and industrial domains over time.
“Labs have invested heavily in instrumentation, but critical decisions still bottleneck on human review,” said Lalin Theverapperuma, Ph.D., Founder and CEO of Expert Intelligence. “We built LSM so regulated labs can scale expertise with accuracy, transparency, and audit readiness from day one. Our models learn directly from how experts interpret raw signals, allowing labs to increase throughput without introducing new compliance risk.”
The new funding will be used to accelerate customer expansion in pharma, deepen integrations across laboratory systems, and build go-to-market and customer success capabilities.
About Expert Intelligence Expert Intelligence builds AI systems that learn how experts make decisions and scale that judgment across regulated laboratory workflows. By operating directly on raw instrument data and learning from limited examples, the technology enables faster, more accurate, and auditable analysis across pharma, diagnostics, and industrial testing, with expansion into food and beverage safety, environmental monitoring, and advanced materials and chemical manufacturing.
About Sierra Ventures Sierra Ventures is an early-stage venture capital firm focused on enterprise and deep technology companies. With a long-standing network of enterprise leaders, Sierra partners closely with founders building category-defining businesses.
Axon Neuroscience’s active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer’s disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant)
SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer’s disease and progressive supranuclear palsy (PSP):
1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer’s Tau Platform (ATP) Combination-Therapy Trial
The Alzheimer’s Tau Platform (ATP) is the first clinical study to systematically combine therapies targeting the two main disease-driving proteins: amyloid and tau. This innovative platform design helps bring promising therapies to patients sooner, reduces the number of participants assigned to placebo, and allows new treatment options to be added quickly as evidence grows. AADvac1 will be evaluated as the first tau-directed regimen, with additional promising medicines to be added in the future.
The Phase 2 trial aims to assess the safety and efficacy of AADvac1 both as a monotherapy and in combination with an approved anti-amyloid monoclonal antibody for Alzheimer’s disease. Approximately up to 450 participants aged 50-80 with late preclinical or early prodromal Alzheimer’s disease will be enrolled.
Progressive supranuclear palsy (PSP) is a rare and rapidly progressing neurodegenerative disease that typically leads to death within approximately seven years of symptom onset. There are currently no approved therapies capable of slowing disease progression.
The new PSP Trial Platform (PTP), led by the University of California, San Francisco, will be conducted at 50 clinical centers across the U.S. and Canada. The study is similarly like the ATP designed as a long-term platform protocol evaluating multiple investigational therapies.
The platform is funded by a five-year NIA/NIH grant of up to USD 75.4 million – one of the largest grants UCSF has ever received for rare neurodegenerative diseases. The initial phase of the platform will test three therapeutics; the first two selected regimens are AADvac1 and AZP2006/Ezeprogind from a French biotechnology company AlzProtect. A third regimen has been selected and will be announced in early 2026. Approximately 440 patients with PSP-Richardson syndrome are expected to be enrolled in all therapeutic arms.
3. Why is AADvac1 a strong Candidate: A Strong Clinical and Scientific Basis
AADvac1 is an active immunotherapy that stimulates the body to generate antibodies against pathological forms of tau protein. In the completed 24-month Phase 2 ADAMANT clinical trial in Alzheimer’s patients, AADvac1 demonstrated:
a favorable safety profile,
a strong immune response (most patients generated high levels of anti-tau antibodies),
pronounced effects on blood and CSF biomarkers of neurodegeneration and neuroinflammation,
supportive clinical effects indicating potential to slow the disease progression, particularly in patients with confirmed tau pathology.
Results from AADvac1’s multi-year development program have been published in leading scientific journals, including Nature Aging, Lancet Neurology, and others. A key recent post-hoc analysis published in Alzheimer’s Research & Therapy further strengthened the evidence that AADvac1 can modulate critical biological processes in Alzheimer’s disease.
Independent scientific and clinical expert groups in the U.S. have therefore selected AADvac1 as one of the first candidates for both platform trials:
in ATP as the first tau-targeted regimen and the first active immunotherapy tested in combination with anti-amyloid antibody therapy,
in the PSP Platform as one of the first two therapies evaluating the potential to slow brain-volume loss and clinical progression in PSP.
4. Global Recognition of Scientific Expertise
Axon Neuroscience was founded in 1999 by a Slovak immunologist Professor Michal Novak, who was part of the MRC Laboratory of Molecular Biology team in Cambridge that identified tau protein as the main component of neurofibrillary pathology in Alzheimer’s disease. For his lifelong contribution to research, he has received prestigious awards including the Alzheimer’s Association Lifetime Achievement Award (2021) and the WHO Prize for Research in Healthcare of the Elderly (2016).
Axon Neuroscience, the company he founded:
is among the pioneers of tau immunotherapy in Alzheimer’s disease and related tauopathies,
has conducted four clinical trials across eight European countries,
was highlighted by independent research led by Karolinska Institutet (2024), which concluded that AADvac1 is among the possible future Alzheimer’s therapies and particularly suitable for combination treatment with amyloid-targeting medicines,
has in its pipeline a promising humanized antibody AADvac2, whose mechanism of action has been indirectly validated by the AADvac1 clinical data and which may offer a more effective treatment for later disease stages or patients with weaker immune responses.
5. Prestigious Collaborations, European Grants, and Partnerships
Axon Neuroscience has received two major Horizon 2020 – Marie Skłodowska-Curie Actions grants, among the prestigious European scientific funding schemes supporting excellent research and the mobility of top scientists. The company also maintains a long-term project partnership with the University of Cambridge, supported by the grants from UK Research and Innovation funding system. Axon further collaborates with leading global pharmaceutical and biotechnology companies on the development of therapeutics for neurodegenerative diseases.
Executive and Scientific Leadership Quotes
Norbert Zilka, DrSc., Chief Scientific Officer: “The selection of AADvac1 for two independent NIA/NIH-funded platform trials led by prestigious U.S. academic centers is a strong confirmation of the high standard of our clinical research. The active tau immunotherapy we have been developing for more than a decade is now rightfully at the forefront of future combination therapies for Alzheimer’s disease and tauopathies.”
Branislav Kovacech, PhD., Chief Operating Officer: “The ATP and PTP platform trials fundamentally change how drugs are developed. Instead of isolated, lengthy, and expensive studies, a dynamic infrastructure is emerging in which the most devastating brain diseases are studied more efficiently – with fewer patients on placebo and faster pathways for promising therapies. This is a major advantage for both patients and investors.”
Michal Fresser, Chief Executive Officer: “The fact that NIH, UCSF, Harvard, and leading U.S. centers have chosen AADvac1 as the first tau therapy in the Alzheimer’s Tau Platform and as one of the first therapies in the PSP Platform is not only a scientific milestone but also a strategic validation of our approach. It is clear evidence that technology developed by our innovators has the potential to become part of future treatment standards for Alzheimer’s disease and PSP.”
Electrical Works Completed; Commissioning Expected to Begin Mid-February
TEL AVIV, IL / ACCESS Newswire / February 4, 2026 / Brenmiller Energy Ltd. (NASDAQ:BNRG) (“Brenmiller”, “Brenmiller Energy” or the “Company”), a provider of thermal energy storage (“TES”) solutions for industrial and utility customers, today provided an operational update on its flagship project for Tempo Beverages Ltd. (“Tempo”).
The Company announced that electrical works at the Tempo site have been completed, marking a major milestone in the project’s development and enabling full electrification of the TES system.
With the completion of this phase, the TES system is now electrically connected and capable of supporting large-scale electric charging, converting electricity into dispatchable industrial heat. The electrical scope included installation and integration of the system’s cabling, transmission infrastructure, switching equipment, and heating components.
Following completion of the electrical works, commissioning activities are expected to begin in mid-February 2026.
“The completion of the electrical works at Tempo is a major milestone for the project,” said Avi Brenmiller, Chief Executive Officer of Brenmiller Energy. “This step enables full electrification of the thermal energy storage system and marks the transition from construction into the final stages ahead of commissioning.”
About the Tempo Project
The Tempo Project is Brenmiller’s flagship industrial deployment and a major milestone in the Company’s evolution from long-term technology development to scaled commercial execution.
The Tempo project is designed to deliver the full replacement of 100% of the site’s natural gas boiler-based heat production through Brenmiller’s thermal energy storage solution. The project includes a 32 megawatt-hour TES installation engineered to supply continuous industrial process heat, eliminating 6,200 tons of CO2 annually.
The Tempo project represents the culmination of more than 15 years of technology development, translating Brenmiller’s patented TES platform into a full-scale industrial reference site. The Company expects the project to serve as an exceptional demonstration for customers, partners, and policymakers, showcasing how thermal energy storage can enable continuous industrial production without routine dependence on fossil fuel combustion.
Brenmiller views the Tempo project as a foundational step toward realizing its growing commercial pipeline, providing a validated template for repeatable deployment of the Company’s TES solutions across industrial applications globally.
About Brenmiller Energy Ltd.
Brenmiller Energy (NASDAQ:BNRG) provides TES solutions that enable industrial and utility customers to decarbonize heat, improve energy flexibility, and integrate renewable electricity. The Company’s bGen™ systems convert electricity into dispatchable industrial heat, supporting electrification and emissions reduction across a range of applications.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements when discussing full electrification of the Company’s TES system at the Tempo project; that the TES system is capable of supporting large-scale electric charging, converting electricity into dispatchable industrial heat; and that commissioning activities are expected to begin in mid-February 2026. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
5E Seeks to Collaborate with U.S. Magnet Producer to Solve Ferroboron Supply Gap
U.S. Supply Chains for Ferroboron are Import-Reliant with Significant Supply Chain Risk Tied to Chinese Manufacturing
HESPERIA, CALIFORNIA / ACCESS Newswire / February 4, 2026 / 5E Advanced Materials, Inc. (“5E” or the “Company”) (Nasdaq:FEAM)(ASX:5EA), a company focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron derivative materials, today announced that it targets future production of Ferroboron and the establishment of a secure, domestic supply chain utilizing upstream feedstock of boric acid produced from its Fort Cady site in California. Ferroboron is an iron-boron alloy used as a boron additive in specialty steel and as a boron source for neodymium-iron-boron (NdFeB) magnet alloy feedstock. NdFeB permanent magnets are essential components in high-efficiency electric motors, wind turbines, industrial automation and defense systems. Recent export controls and geopolitical friction have reinforced investors’ and customers’ focus on domestic magnet supply chains, where global manufacturing remains highly concentrated. The U.S. currently has no domestic production of ferroboron, creating a critical dependency within specialty steel and permanent magnet supply chains.
Key Takeaways:
Advances 5E towards realizing its longer-term mission of providing higher value boron derivatives
Targets a higher-value boron derivative (ferroboron), leveraging Fort Cady boric acid as upstream feedstock.
Addresses a U.S. vulnerability: USGS has noted the U.S. does not produce ferroboron and relies on imports.
Positions 5E to support domestic NdFeB magnet supply chains amid high global concentration in rare-earth magnets.
This initiative reflects 5E’s strategy to expand beyond commodity borates into higher-value derivative materials, potentially enhancing long-term revenue mix, strategic relevance, and customer integration.
“5E’s vision has always been to derivatize its upstream feedstock and transition down the value chain. Today the U.S. is import-reliant for ferroboron, a critical component in permanent magnet manufacturing,” said Paul Weibel, Chief Executive Officer. “While there has been an obvious need to reinforce the supply chains for rare earths and permanent magnets, the U.S. has a ferroboron deficiency and following engagement with U.S. magnet manufacturers, there is a clear demand and need for a reliable and vertical supply chain in the U.S. 5E has the capability and reliable upstream feedstock to serve that need.”
The Company has initiated structured evaluations of engineering pathways, capital requirements, and partnership frameworks. Any production timeline is subject to technical validation, commercial alignment, and financing.
About 5E Advanced Materials, Inc.
5E Advanced Materials, Inc. (Nasdaq:FEAM)(ASX:5EA) is focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron materials, complemented by calcium-based co-products, and potentially other by-products such as lithium carbonate. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, energy independence, food, national security, and the defense sector. The Company believes factors such as government regulation and incentives focused on domestic manufacturing and supply chains and capital investments across industries will drive demand for end-use applications like solar and wind energy infrastructure, neodymium-ferro-boron magnets, defense applications, lithium-ion batteries, and other critical material applications. The business is based on the Company’s large domestic boron resource, which is located in Southern California and designated as Critical Infrastructure by the U.S. Department of Homeland Security, and boron was included on the U.S. Government’s 2025 Critical Minerals List.
Forward Looking Statements
Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, and include, but are not limited to, statements regarding the Company’s development plans, production capabilities, commercialization strategy, offtake discussions, customer qualification processes and success thereof, market demand for boron and lithium, the potential applications of its products across energy, defense, agriculture and industrial markets, and ability to access and secure any government-based financing. Any forward-looking statements are based on 5E’s current expectations, forecasts, and assumptions and are subject to a number of risks and uncertainties that could cause actual outcomes and results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements regarding the Company’s development plans, production capabilities, commercialization strategy, offtake discussions, customer qualification processes, market demand for boron and lithium, and potential applications of its products across energy, defense, and industrial markets, and ability to access and secure any government-based financing. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in 5E’s most recent Annual Report on Form 10-K and its other reports filed with the SEC. Forward-looking statements contained in this announcement are based on information available to 5E as of the date hereof and are made only as of the date of this release. 5E undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing 5E’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of 5E.
Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed
Reports Cash and Investments of approximately $28 million as of the Year Ended December 31, 2025
IRVINE, CA / ACCESS Newswire / February 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno Medical” or the “Company”), today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed that for the last 10 consecutive business days, from January 20, 2026 through February 2, 2026, the closing bid price of the Company’s common stock was at or above $1.00, and as a result, the matter is now closed.
The Company has made meaningful progress on its 2026 strategic plans and expects to share additional details in the coming weeks. The Company believes that regaining compliance with listing requirements, combined with a year-end cash and investments balance of approximately $28 million as of December 31, 2025, positions it well for 2026.
About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S.
Ori Gon brings substantial public company, medtech, and capital markets experience
HERZLIYA, ISRAEL / ACCESS Newswire / February 4, 2026 / Regentis Biomaterials Ltd., (“Regentis” or the “Company”) (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the appointment of Ori Gon as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gon will lead the Company’s commercial and business development activities, as well as its financial strategy, planning, and reporting.
Mr. Gon joins Regentis at a pivotal time as GelrinC®, the Company’s proprietary hydrogel implant for knee cartilage repair, advances towards commercial launch in Europe following CE Mark approval and is being evaluated in a pivotal Phase III FDA clinical trial in the United States.
“Ori’s appointment significantly strengthens our leadership team as we transition from a development-stage company toward commercialization,” said Dr. Ehud Geller, Executive Chairman of Regentis. “His deep experience as a public company CFO, combined with his strategic business development expertise, will be instrumental as we evaluate strategic partnerships to launch GelrinC® in Europe and build the foundation for sustainable, revenue-generating growth.”
Mr. Gon brings over 15 years of financial leadership experience across public and private enterprises and medical technology. Most recently, he served as CFO at Tactile Mobility, a sensing and data analytics company focused on advanced automotive and mobility applications. Prior to that, he held senior financial leadership roles at ReWalk Robotics, Inc., now Nasdaq-listed Lifeward Ltd., a pioneer in wearable robotic exoskeletons for individuals with lower limb disabilities, where he served as CFO and Corporate Controller. Earlier in his career, he was Controller at On Track Innovations Ltd., a Nasdaq- and Neuer Markt-listed fintech company. He began his professional career as an auditor at KPMG Israel.
Mr. Gon has led multiple secondary public offerings and financing transactions across various structures, raising over $150 million in aggregate capital. He is a Certified Public Accountant (CPA) in Israel.
“I am excited to join Regentis at such an important inflection point,” said Ori Gon. “With GelrinC® approaching commercialization in Europe and progressing through a pivotal FDA trial in the U.S., we believe Regentis is uniquely positioned to transform the treatment landscape for knee cartilage repair. I look forward to working with the team to execute our commercial strategy, build strategic partnerships, and create long-term value for patients and stakeholders.”
About GelrinC®
Regentis’ lead product, GelrinC®, is a cell-free, off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. As an innovative regenerative medical product, GelrinC® offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. No effective off-the-shelf, ready to use treatment for focal knee cartilage defects is currently available on the market. GelrinC® has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.
About Regentis Biomaterials
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include beliefs regarding Regentis’ advancement towards commercialization. Forward-looking statements are based on Regentis’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the ability of our clinical trials to demonstrate safety and efficacy of GelrinC or any future product candidate, and other positive results; the timing and focus of our preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for of GelrinC or any future product candidate, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to accurately identify demand for product candidates; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain FDA approval for of GelrinC or any future product candidate and obtain and maintain regulatory approval; our ability to obtain market acceptance of of GelrinC or any future product candidate from the medical community and third-party payors; our plans relating to the further development of GelrinC or any future product candidate, including additional disease states or indications we may pursue; existing regulations and regulatory developments in the United States and other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our dependence on third parties; our financial performance and our ability to repay our loans and debts; and our ability to negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.
Now available at Costco, the Swash CL150 marks an expansion of Brondell’s product lineup and fast-growing, non-electric bidet toilet seat segment.
SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Brondell, the leading bidet manufacturer in North America since 2003, announces the release of the Swash CL150 Non-Electric Bidet Toilet Seat. The Swash CL150 is available on Costco.com and in Costco locations around the United States.
The release of the Swash CL150 builds on Brondell’s 16-year partnership with Costco and expands its portfolio of advanced bidets, water filtration systems, and high-performance showerheads.
“Costco has been an outstanding long-term partner,” said Steven Scheer, President of Brondell. “We’re thrilled to bring our latest innovation, the CL150 Non-Electric Bidet Toilet Seat, to Costco members. This new seat is a feature-packed solution that transforms any standard toilet into a bidet in minutes, delivering exceptional performance, hygiene, and value.”
The Swash CL150’s release serves a fast-growing segment of consumers who are looking for a bidet toilet seat that functions without electricity. With a streamlined frame and wrap-over lid, the Swash CL150 offers a sleek, modern design and advanced features that improve personal hygiene and drive sustainability by reducing toilet paper.
The Swash CL150 leverages over 23 years of bidet-manufacturing experience in the North American market. Powered by Brondell’s innovative nozzle design, the Swash CL150 provides a hygienic, personalized wash experience with self-cleaning features that maintain the bidet’s cleanliness during use.
The Swash CL150 top features include:
Sleek wrap-over lid for a modern appearance in any bathroom
Dual nozzles provide separate front and rear washes
Easy-to-use, planet-friendly trivalent chrome-plated control dial adjusts wash mode and water pressure
Self-cleaning, retractable nozzles maintain hygiene between uses
Gentle-close seat and lid with quick-release button for easy cleaning
Sturdy, anti-slip bumpers add stability and comfort
Holds trusted cUPC certification
Durable brass water inlet provides secure, leak-free connection
Continuing Brondell’s commitment to the planet, the Swash CL150 gives Costco customers in North America a sustainable alternative to traditional toilet paper. Toilet paper manufacturing can be an environmentally intensive process, often involving the harvesting of old-growth forests. Featuring dual, hygienic nozzles, the Swash CL150’s eco-friendly wash helps conserve trees and natural resources by reducing the need for toilet paper.
Designed for easy installation and to withstand the stress of everyday use, the Swash CL150’s high-quality parts are user-friendly and built to last. The Swash CL150’s components include a durable brass inlet connection, stainless steel T-Valve, and long-lasting, braided-metal elbow hose. Simple, top-mounting bolts make setup quick and simple without the need for a plumber or complicated tools.
With over 23 years in the industry, Brondell is the leader in developing products that provide welcome relief, long-term health benefits, and a more sustainable footprint for healthier spaces and routines. The company focuses on customer wellness, harnessing cutting-edge technology to improve health within the home, office, commercial spaces, and beyond. Product development includes rigorous, independent laboratory testing, thoughtful designs, and third-party certifications for a reduction in airborne particulates, waterborne contaminants, and wasteful toilet paper usage. Brondell’s products have earned numerous accolades, including the Best of KBIS Silver Award for Kitchen 2015, KBIS 30 Under 30 Wellness and Health Award 2023, and the KBB Award Best Kitchen Accessory 2022.
In addition, Brondell is the first company to bring to market a bidet toilet seat designed for commercial spaces, including spas, hotels, and more. Whether for business or personal use, each product in Brondell’s ecosystem of solutions is crafted to fit seamlessly and sustainably into everyday life, so that things we do every day-like breathing, drinking, bathing, flushing, and washing-are better for both people and the planet.
Brondell is a Mark Cuban-backed company with a retail presence in 5,000+ stores throughout North America. The company acquired Nebia in February 2023, expanding its Bathe category and building a portfolio of innovative, water-saving technology products.
UWGEAM LLC announces the release of a new music project from recording artist Darrell Kelley, supported by official video, audio, and photo assets distributed through established digital media outlets. The release highlights UWGEAM LLC’s role as the originating source and publisher of all associated multimedia content.
## Darrell Kelley Releases New Single “Ice Cold Killerz”
ATLANTA, GA / ACCESS Newswire / February 3, 2026 / UWGEAM LLC proudly announces the release of *”Ice Cold Killerz”*, the latest single from recording artist Darrell Kelley. The new track delivers a confident, high‑energy sound while addressing serious real‑world events through artistic expression.
“Ice Cold Killerz” blends modern production with assertive lyricism, reinforcing Darrell Kelley’s presence within today’s independent music landscape. **The song was written in reference to Renée Good and Alex Pretti, with its thematic focus tied to the concept of ice killing them and events associated with Minneapolis, Minnesota.** The record uses symbolism and narrative to convey its message within a musical framework.
The release is supported by official promotional visuals, including YouTube‑hosted video content and photography, all produced, managed, and distributed by UWGEAM LLC.
This announcement represents a coordinated digital media rollout designed to expand audience reach across music streaming services, social platforms, and video outlets. UWGEAM LLC serves as the owner, publisher, and distributor of the multimedia assets referenced in this release.
“Ice Cold Killerz” is now available through major digital music platforms, with supporting media accessible through Darrell Kelley’s official outlets and UWGEAM LLC’s corporate website.
## Official Media Outlets & Digital Platforms
Darrell Kelley maintains an active presence across verified digital and media platforms, including:
– **Instagram (Official)** – https://www.instagram.com/darrellkelleyofficial – **YouTube (Official Video)** – https://youtu.be/zD3IsSuwF_U?si=ySzTHwQ5QMryuchm – **YouTube** – Official music videos and visual content – **Spotify** – Official music releases and artist catalog – **Apple Music** – Digital music streaming and downloads – **Amazon Music** – Music availability and discovery – **SoundCloud** – Independent releases and promotional audio – **Facebook** – Official announcements and fan engagement
These contact details serve as the official channels for media inquiries, interviews, licensing, partnerships, and booking requests.
## About Darrell Kelley
Darrell Kelley is an independent recording artist recognized for his expressive delivery and authentic musical style. His work emphasizes originality, confidence, and creative independence, supported by consistent releases and visual storytelling across digital platforms.
## About UWGEAM LLC
UWGEAM LLC is a U.S.-based media and digital content company specializing in the production, management, and distribution of original multimedia content. The company oversees music releases, video production, photography, and strategic digital media campaigns. UWGEAM LLC is the official source and publisher of all assets associated with this release.
Formal process to evaluate ‘Stage 1′ financing strategy in parallel with DFS
HIGHLIGHTS
Definitive Feasibility Study (DFS) and upgrade drilling underway for ‘Stage 1′ operations at Central Gawler Mill (CGM), following dual Challenger JORC (2012) Mineral Resources upgrades to 313koz Au1
Early discussions underway with multiple credit, minerals trading and other investment groups who have approached Barton with an interest to participate in and / or finance ‘Stage 1′ operations
Bedrock Advisory Partners appointed to manage credit portion of Barton’s ‘Stage 1′ finance process
ADELAIDE, AU / ACCESS Newswire / February 3, 2026 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or Company) is pleased to announce the appointment of Bedrock Advisory Partners (Bedrock) to manage the credit portion of Barton’s financing process for targeted ‘Stage 1′ operations at its South Australian Challenger Gold Project (Challenger).
Barton’s wholly-owned Central Gawler Mill (CGM) is the region’s only gold mill, located adjacent to Challenger. This provides Barton material leverage for a relatively low-cost, de-risked transition to operations. An ongoing DFS is targeting baseline ‘Stage 1′ operations using only historical higher-grade tailings and limited near-surface materials, to maximise Challenger underground, Tarcoola, Wudinna and Tolmer development optionality.
The Company has held early discussions with a wide range of minerals investment, trading, and credit finance groups interested to participate in or finance planned ‘Stage 1′ operations on a wide range of indicative terms. Bedrock will assist Barton to formalise and manage a thorough process to evaluate these potential options.
Bedrock’s leadership team has decades of natural resources finance experience with firms such as BNP Paribas, Royal Bank of Canada and NM Rothschild & Sons, and has successfully completed A$ billions of financings for Australian precious metals groups such as Ramelius, Northern Star, Vault (Red 5), OceanaGold, and Gold Road.
Bedrock’s credit and technical expertise will enhance Barton’s own capacity and supplement its demonstrated in-house capabilities in metals trading and equity capital markets. Bedrock will also assist with operational and credit risk modelling to optimise and de-risk Barton’s investment strategy and transition to ‘Stage 1′ operations.
Commenting on the appointment of Bedrock Advisory Partners, Barton MD Alexander Scanlon said:
“With record high gold prices and over 300koz Au JORC Resources confirmed, the opportunity to leverage our existing, fully permitted infrastructure at the Central Gawler Mill to ‘Stage 1′ operations has never been more attractive.
“Reinstatement of the CGM will also materially enhance the exploration and development optionality of the historical high-grade Challenger underground mine and Barton’s ‘regional enhancement’ assets Tarcoola, Tolmer and Wudinna, each of which could potentially provide high-grade gold and silver mineralisation for processing through the CGM.
“We will evaluate a range of potential ‘Stage 1′ financing options which may include a combination of conventional or structured credit, trade finance, commodities trading, and equity approaches. Based upon a thorough evaluation of options, and how these may complement the results of our ‘Stage 1′ DFS, we will pursue the best approach for Barton. Bedrock’s deep credit and technical expertise will be an invaluable asset to the ongoing refinement of our strategies
1 Refer to ASX announcements dated 30 June and 8 / 28 September 2025, and 2 February 2026
Authorised by the Board of Directors of Barton Gold Holdings Limited.
Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 2.2Moz Au & 3.1Moz Ag JORC Mineral Resources (79.9Mt @ 0.87g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*
Challenger Gold Project
313koz Au + fully permitted Central Gawler Mill (CGM)
Tarcoola Gold Project
20koz Au in fully permitted open pit mine near CGM
Tolmer discovery grades up to 84g/t Au & 17,600g/t Ag
Competent Persons Statement & Previously Reported Information
The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).
Activity
Competent Person
Membership
Status
Tarcoola Mineral Resource (Stockpiles)
Dr Andrew Fowler (Consultant)
AusIMM
Member
Tarcoola Mineral Resource (Perseverance Mine)
Mr Ian Taylor (Consultant)
AusIMM
Fellow
Tarcoola Exploration Results (until 15 Nov 2021)
Mr Colin Skidmore (Consultant)
AIG
Member
Tarcoola Exploration Results (after 15 Nov 2021)
Mr Marc Twining (Employee)
AusIMM
Member
Tunkillia Exploration Results (until 15 Nov 2021)
Mr Colin Skidmore (Consultant)
AIG
Member
Tunkillia Exploration Results (after 15 Nov 2021)
Mr Marc Twining (Employee)
AusIMM
Member
Tunkillia Mineral Resource
Mr Ian Taylor (Consultant)
AusIMM
Fellow
Challenger Mineral Resource (above 215mRL)
Mr Ian Taylor (Consultant)
AusIMM
Fellow
Challenger Mineral Resource (below 90mRL)
Mr Dale Sims
AusIMM / AIG
Fellow / Member
Wudinna Mineral Resource (Clarke Deposit)
Ms Justine Tracey
AusIMM
Member
Wudinna Mineral Resource (all other Deposits)
Mrs Christine Standing
AusIMM / AIG
Member / Member
The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. In accordance with ASX Listing Rule 5.19.2, the Company further confirms that the material assumptions underpinning any production targets and the forecast financial information derived therefrom continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.
Cautionary Statement Regarding Forward-Looking Information
This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.
* Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 8 September 2025. Total Barton JORC (2012) Mineral Resources include 1,049koz Au (39.7Mt @ 0.82 g/t Au) in Indicated category and 1,186koz Au (40.2Mt @ 0.92 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.
TOKYO, JP / ACCESS Newswire / February 3, 2026 / Perpetuals.com Ltd. (Nasdaq:PDC) (“Perpetuals.com” or the “Company”), a regulated financial technology company combining blockchain infrastructure and artificial intelligence to transform digital asset trading, today announced the successful completion of a BayesShield™ AI pilot program(the “BayesShield™ AI Pilot Program”). The pilot has demonstrated the system’s ability to filter out 92% of losing retail trades in the BTC-USD-PERP perpetual futures market, based on backtesting against a full year of actual retail trading data.
The BayesShield™ AI Pilot Program validated the Company’s proprietary machine learning models by analyzing historical retail trading behavior in the Bitcoin perpetual futures market. When applied to 12 months of real retail trade data, the AI system successfully identified and would have filtered 92% of trades that ultimately resulted in losses for retail participants.
“These pilot results exceed our expectations and validate years of research into retail trading behavior,” said Patrick Gruhn (“Mr. Gruhn”), the CEO and the founder of Perpetuals.com. “The data show that the vast majority of retail losses in leveraged derivatives markets are predictable and preventable. BayesShield™ represents a paradigm shift in how trading platforms can protect their users while maintaining market integrity.”
Amid the current downturn in cryptocurrency prices, which has tested trader resilience across the board with sharp price corrections, the BayesShield™ AI Pilot Program demonstrates exceptional real-world utility. For example, its predictive intelligence identifies and blocks the majority of losing trades before execution, providing critical protection in turbulent markets while reinforcing crypto’s fundamental robustness and long-term growth potential.
The BayesShield™ AI Pilot Program analyzes the specific profit and loss profiles of individual traders, identifying patterns in collective market sentiment to calculate win/loss probability in real-time. The system is designed to help product issuers-such as options writers, market makers, and derivatives platforms-optimize hedging strategies while providing enhanced protection for retail participants.
“The retail derivatives market has historically operated on a model where the majority of participants lose money,” continued Mr.Gruhn. “BayesShield™ fundamentally changes this dynamic. By predicting which trades are likely to fail before they execute, we can create trading environments that are both more ethical and more sustainable for all participants.”
Building on the pilot’s success, Perpetuals.com has commenced full-scale development of the BayesShield™ AI Pilot Platform. The production system is being trained on NVIDIA hardware on one of the largest retail trading datasets ever assembled:
Over 11.7 billion individual retail trades spanning multiple years of market activity
More than 1 million unique user trading histories providing statistically significant behavioral patterns
Cryptocurrency spot markets including Bitcoin, Ethereum, and major altcoins
Cryptocurrency derivatives, including perpetual futures, options, and leveraged products
Traditional stock markets, enabling cross-asset pattern recognition and model validation
Protecting Retail Traders Through Predictive Intelligence
The announcement coincides with the successful completion of the Company’s technical integration following its business combination with EarlyWorks Co., Ltd. This integration consolidated technology stacks, operational infrastructure, and data systems into a unified platform. The redesigned website at perpetuals.com now serves as the central hub for all products and services, including the Kronos X®exchange suite, Perpetuals Vault custody solutions, Ledgera cross-chain infrastructure, PerpetualPay.net, and tokenization services, reflecting the Company’s expanded capabilities and unified brand identity.
The BayesShield™ AI Pilot Program positions Perpetuals.com to address systemic inefficiencies and ethical concerns in retail derivatives trading-a segment that has faced increasing regulatory scrutiny globally due to high retail loss rates.
The Company plans to deploy the BayesShield™ AI Pilot Program across its regulated trading infrastructure, including to a third-party, CySEC-authorized MiFID II-licensed Multilateral Trading Facility, with a broader commercial rollout planned for the second half of the year. Institutional partners, trading platforms, and product issuers interested in early access or integration discussions can contact the Company through perpetuals.com.
About Perpetuals.com Ltd.
Perpetuals.com (NASDAQ:PDC) is a financial technology company that combines blockchain infrastructure and artificial intelligence to transform digital asset trading. The Company develops and operates Kronos X®, a proprietary, multi-asset exchange platform and blockchain-based settlement solution fully compliant with European regulations, including MiCA, DORA, and EMIR. The Company provides financial market infrastructure as a service from Equinix FR2 in Frankfurt, Germany, alongside Eurex and Xetra, enabling clients to operate 24/7 trading of crypto spot, derivatives, tokenized securities, and structured products.
The Perpetuals.com team pioneered regulated tokenized financial products, including Pre-IPO contracts for Coinbase, Airbnb, and Robinhood-as reported by Forbes-as well as tokenized stocks traded on major exchanges. Building on machine-learning analysis of millions of retail trade transactions, the Company has developed AI-powered risk intelligence designed to analyze trading patterns in real-time.
Trademark Information: Kronos X® is a registered trademark in the European Union under filing number 019097099 and a pending trademark registration in the United States. Perpetuals.com™ is the subject of a pending trademark application in the European Union under filing number 019186468. Ledgera™ is pending trademark registration in the United States and Europe. PerpetualsPay.Net™ is a registered trademark in the European Union and the United Kingdom. BayesShield™ is a pending trademark registration in the European Union and the United States.
Forward-Looking Statements: This press release contains forward-looking statements as defined within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements set forth in the Company’s filings with the Securities and Exchange Commission. Words such as “expect”, “will”, “positions”, “advancing”, “aligning”, and other similar expressions may indicate forward-looking statements, though not all forward-looking statements contain such words. These statements reflect the Company’s current view with respect to future events, are subject to risks and uncertainties that could cause actual results to differ materially, including regulatory approvals, completion of the announced transaction, market conditions, and risks detailed in the Company’s SEC filings, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties, and contingencies. Should one or more of these risks or uncertainties materialize, or should the assumptions set out by the Company underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law.
